Compare Stocks → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison TSE:ONCNASDAQ:ORPHTSE:RVX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeONCOncolytics BiotechC$1.45+5.1%C$1.46C$1.20▼C$4.49C$109.36M1.4975,475 shs83,473 shsORPHOrphazyme A/S$1.43$0.51▼$77.77$30.72M1.681.37 million shs941,400 shsRVXResverlogixC$0.06C$0.06C$0.06▼C$0.26C$14.97M0.7839,503 shs19,000 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceONCOncolytics Biotech+5.07%+4.32%+1.40%-18.99%-9.94%ORPHOrphazyme A/S0.00%0.00%0.00%0.00%0.00%RVXResverlogix0.00%0.00%-8.33%-21.43%-62.07%Central Banks Preparing for US Dollar Collapse? (Ad)China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationONCOncolytics Biotech0.4473 of 5 stars3.50.00.00.00.00.00.0ORPHOrphazyme A/SN/AN/AN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceONCOncolytics Biotech3.00BuyC$9.00520.69% UpsideORPHOrphazyme A/SN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/ACurrent Analyst RatingsLatest REDX, DDDD, ONC, RVX, and ORPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails1/12/2024ONCOncolytics BiotechCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight(Data available from 3/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookONCOncolytics BiotechN/AN/AC$0.34 per share4.22C$0.37 per shareN/AORPHOrphazyme A/SN/AN/AN/AN/A$2.74 per shareN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.26) per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateONCOncolytics Biotech-C$27.75M-C$0.41N/A∞N/AN/A-102.66%-55.47%5/3/2024 (Estimated)ORPHOrphazyme A/S-$97.01MN/A0.00N/AN/AN/AN/AN/AN/ARVXResverlogix-C$12.82M-C$0.05N/A∞N/AN/AN/A-37.10%3/29/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthONCOncolytics BiotechN/AN/AN/AN/AN/AORPHOrphazyme A/SN/AN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioONCOncolytics Biotech1.549.018.86ORPHOrphazyme A/S0.141.80N/ARVXResverlogixN/A0.110.04OwnershipInstitutional OwnershipCompanyInstitutional OwnershipONCOncolytics Biotech6.98%ORPHOrphazyme A/S10.74%RVXResverlogixN/AInsider OwnershipCompanyInsider OwnershipONCOncolytics Biotech1.14%ORPHOrphazyme A/SN/ARVXResverlogix43.33%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableONCOncolytics Biotech2975.42 millionN/ANot OptionableORPHOrphazyme A/S14135.31 millionN/ANot OptionableRVXResverlogix19272.17 millionN/ANot OptionableREDX, DDDD, ONC, RVX, and ORPH HeadlinesSourceHeadlineResverlogix Announces Change to Its Board of Directorsfinance.yahoo.com - February 21 at 8:02 PMResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefitsfinance.yahoo.com - January 11 at 10:03 AMClosing Bell: Resverlogix Corp flat on Tuesday (RVX)theglobeandmail.com - January 4 at 6:16 PMResverlogix Corp. (RVX) Earnings Dates & Reportsinvesting.com - December 19 at 7:28 PMResverlogix Corp RVXCFmorningstar.com - November 18 at 5:49 PMResverlogix Corp RVXmorningstar.com - November 1 at 11:18 AMResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)theglobeandmail.com - October 18 at 7:46 AMResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophyfinanznachrichten.de - October 4 at 10:11 AMResverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular Dystrophyfinance.yahoo.com - October 4 at 10:11 AMAtherosclerotic Cardiovascular Disease Market to Observe Impressive Growth at a CAGR of 2.2% by 2032, Predicts DelveInsightfinance.yahoo.com - September 26 at 8:50 PMResverlogix Announces a Favorable Outlook Based on New Cardiovascular Disease Treatment Guidelines for Patients with Type 2 Diabetesfinance.yahoo.com - August 29 at 10:13 AMClosing Bell: Resverlogix Corp up on Wednesday (RVX)theglobeandmail.com - August 24 at 3:35 PMClosing Bell: Resverlogix Corp flat on Monday (RVX)theglobeandmail.com - August 14 at 10:02 PMClosing Bell: Resverlogix Corp Warrants down on Wednesday (RVX-WT-A)theglobeandmail.com - July 12 at 7:21 AMResverlogix Announces Warrant Repricing and One-Year Extensionfinance.yahoo.com - June 29 at 11:09 PMResverlogix Corp.: Resverlogix Announces Voting Results from the 2023 Meeting of Shareholdersfinanznachrichten.de - June 20 at 7:31 PMResverlogix Announces Voting Results from the 2023 Meeting of Shareholdersfinance.yahoo.com - June 20 at 7:31 PMResverlogix Announces New Insights into the Mechanism of Apabetalone's Cardioprotective Benefit in Chronic Kidney Disease Patientsfinance.yahoo.com - June 12 at 6:42 PMCanadian Investment Regulatory Organization Trading Halt - RVX.WT.Afinance.yahoo.com - June 7 at 1:32 PMClosing Bell: Resverlogix Corp Warrants down on Friday (RVX-WT-A)theglobeandmail.com - June 6 at 10:49 AMClosing Bell: Resverlogix Corp Warrants down on Tuesday (RVX-WT-A)theglobeandmail.com - May 25 at 12:52 AMCBOE RUSSELL 2000 VOLATILITY IN (^RVX)finance.yahoo.com - May 18 at 12:38 AMBromodomain Containing Protein 2 Market is Likely to Upsurge at ... - StreetBuzznews.google.com - May 13 at 3:47 PMResverlogix : MD&A Q1 2023 - Marketscreener.comnews.google.com - May 12 at 3:50 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesMastering Stocks in the Dow: Insights into the DJIAMarch 14, 2024 10:51 AMView Mastering Stocks in the Dow: Insights into the DJIAMarketBeat Week in Review – 3/11 – 3/15March 16, 2024 7:00 AMView MarketBeat Week in Review – 3/11 – 3/15Okta Raises EPS Forecasts Despite High Profile Security BreachesMarch 7, 2024 6:23 AMView Okta Raises EPS Forecasts Despite High Profile Security BreachesTesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?March 26, 2024 7:00 AMView Tesla Is the Analyst's Most Downgraded Stock: How Low Can It Go?Kroger Stock: Anticipating New Highs as Promising Uptrend ResumesMarch 12, 2024 7:30 AMView Kroger Stock: Anticipating New Highs as Promising Uptrend ResumesAll Headlines Company DescriptionsOncolytics BiotechTSE:ONCOncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and Bavencio, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Orphazyme A/SNASDAQ:ORPHOrphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on the amplification of heat-shock proteins to develop and commercialize therapeutics for diseases caused by protein misfolding and aggregation, and lysosomal dysfunction, including lysosomal storage and neuromuscular degenerative diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Amyotrophic Lateral Sclerosis, Inclusion Body Myositis, and Gaucher disease. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.ResverlogixTSE:RVXResverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada; and developing cardiovascular and pulmonary arterial hypertension indications. The company was founded in 2001 and is headquartered in Calgary, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.